Az St-Jan Brugge-Oostende A.V.
Brugge, Belgium
Not recruiting
Study on Rezafungin to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
Fast replyRegistered drug
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the prevention of invasive fungal diseases in adults who are undergoing a type of blood and marrow transplant known as allogeneic transplantation. The study will compare the effectiveness and safety of a new treatment called Rezafungin for injection against the standard antimicrobial treatments currently used. The goal is to see if Rezafungin can help patients survive without fungal infections for 90 days after their transplant.
Participants in the study will receive either Rezafungin or the standard treatment. The standard treatment may include medications like Bactrim (which contains sulfamethoxazole and trimethoprim), Diflucan (fluconazole), and Noxafil (posaconazole). Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will monitor participants for 90 days to check for survival and the absence of fungal infections.
The study aims to determine if Rezafungin is as effective as, or better than, the standard treatments in preventing fungal infections. Participants will be closely monitored for any side effects or intolerances to the medications. The study will also track the number of fungal infections and any deaths that occur during the study period. This research is important for improving the care and outcomes of patients undergoing allogeneic blood and marrow transplants.
The research process
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
25 criteria
- Willing and able to provide written informed consent.
- Females who can have children and are less than 2 years post-menopausal must use one barrier method of birth control (like a female condom with spermicide) plus another effective method (like birth control pills or an implant) or practice sexual abstinence during the study and for 30 days after the last dose of the study drug. Males must be vasectomized, abstain from sexual intercourse, or use barrier contraception (like a condom with spermicide) and agree not to donate sperm during the study and for 120 days after the last dose of the study drug.
- Must be 18 years of age or older.
- Receiving a **human leukocyte antigen (HLA)** matched allogeneic peripheral blood and marrow transplant (BMT) from a family or unrelated donor, HLA-mismatched related or unrelated donor, or haploidentical donor. **HLA** is a protein that helps the body recognize its own cells.
- Diagnosed with one of the following diseases:
- Acute myeloid leukemia (AML) in first or second complete remission.
- Acute lymphoblastic leukemia in first or second complete remission.
- Acute undifferentiated leukemia in first or second remission.
- Acute biphenotypic leukemia in first or second complete remission.
- Chronic myelogenous leukemia in chronic or accelerated phase.
- Myelodysplastic syndromes, which are a group of disorders caused by poorly formed or dysfunctional blood cells.
- Lymphoma with chemosensitive disease, meaning it responds to chemotherapy.
- Aplastic anemia, a condition where the body stops producing enough new blood cells.
- Primary or secondary myelofibrosis, a disorder of the bone marrow.
- Chronic myelomonocytic leukemia.
- Chronic lymphocytic leukemia.
- Drepanocytosis, also known as sickle cell anemia.
- Red blood cell aplasia, a condition where the body stops producing red blood cells.
- Myeloproliferative disorder, unclassified.
- Multiple myeloma, a cancer of plasma cells.
- Receiving **myeloablative** or reduced-intensity conditioning regimens. **Myeloablative** means treatments that destroy bone marrow cells.
- Have adequate liver and kidney function before starting the conditioning regimen, which is between 40 days and 10 days before the BMT. This means:
- Liver: **alanine aminotransferase** (a liver enzyme) should be no more than 2.5 times the upper limit of normal, and total serum bilirubin (a substance made by the liver) should be no more than 1.5 times the upper limit of normal, excluding Gilbert’s Syndrome.
- Kidneys: **serum creatinine** (a waste product in the blood) should be no more than 2 mg/dL, and creatinine clearance (a measure of kidney function) should be at least 30 mL/min without a history of kidney transplant or undergoing weekly dialysis within 4 weeks of the BMT.
- Baseline blood samples for specific tests (serum Platelia galactomannan enzyme immunoassay and **β-D-glucan** levels) must be taken within 15 days before randomization, with results available before randomization.
- Baseline **Toxoplasma** serologies (blood tests for a specific infection) must be available within 6 weeks before randomization. If a subject has a positive **Toxoplasma IgG** serology at any time before randomization, they do not need to repeat the tests and will be considered to have a prior history of **toxoplasmosis**.
- Baseline **glucose-6-phosphate dehydrogenase (G6PD)** deficiency determination must be done by the investigator before randomization, with no evidence of known **G6PD** deficiency. If the investigator assesses the subject as **G6PD** sufficient, the test result does not need to be entered into the electronic data capture system.
Who cannot join the trial?
8 criteria
- Patients who have a known allergy or severe reaction to the study medication or similar drugs.
- Patients who are currently participating in another clinical trial or have recently participated in one.
- Patients with a history of certain serious medical conditions that could interfere with the study, such as severe liver or kidney disease.
- Patients who are pregnant or breastfeeding.
- Patients who have a current infection that requires treatment with certain medications that could interfere with the study.
- Patients who have received certain treatments or medications that could affect the study results within a specific time frame before the study starts.
- Patients who have a history of substance abuse or other conditions that could affect their ability to follow the study procedures.
- Patients who have any other condition that, in the opinion of the study doctor, makes them unsuitable for participation in the study.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Verified Responsive Istituto Europeo Di Oncologia S.r.l.
Milan, ItalyResponsive Katholieke Universiteit te Leuven
Leuven, Belgium
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Rezafungin for Injection
is a medication being studied to prevent invasive fungal diseases in adults who have undergone a blood and marrow transplant. It is being compared to the standard treatment to see if it is as effective or better at keeping patients free from fungal infections 90 days after their transplant.
Standard Antimicrobial Regimen (SAR)
refers to the usual treatment given to prevent fungal infections in patients who have had a blood and marrow transplant. This regimen is used as a comparison to evaluate the effectiveness of Rezafungin in preventing these infections.
What is already known about the treatment
Rezafungin – Rezafungin is administered as an injection and is currently being studied in clinical trials for its effectiveness and safety in preventing invasive fungal diseases in adults undergoing allogeneic blood and marrow transplantation. It is in the late stages of clinical research, specifically in a Phase 3 trial, and is being compared to standard antimicrobial treatments. The main therapeutic indication for Rezafungin is the prevention of invasive fungal infections in this patient group. At the molecular level, Rezafungin works by inhibiting the synthesis of essential components of the fungal cell wall, thereby preventing fungal growth and survival. It is classified pharmacologically as an antifungal agent.
Investigated diseases
Invasive Fungal Diseases – These are serious infections caused by fungi that invade the body, often affecting individuals with weakened immune systems, such as those undergoing allogeneic blood and marrow transplantation. The disease can progress rapidly, leading to severe complications if not managed promptly. Common fungi involved include species like Candida, Aspergillus, and Pneumocystis jirovecii. Symptoms may vary depending on the affected area but often include fever, cough, and difficulty breathing. The disease can spread to various organs, causing systemic issues. Early detection and management are crucial to prevent further complications.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-514471-18-00Protocol codeCD101.IV.3.08Estimated enrolment630 patientsSponsorMundipharma Research Limited
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?